Cellectar Biosciences and ITM Isotope Technologies Munich SE (ITM) have entered into a supply agreement for Actinium-225 (Ac-225), the companies announced recently.

According to a release, the agreement will support the clinical development of Cellectar’s actinium-labeled phospholipid ether (PLE) radiopharmaceutical candidates, including its Phase 1-ready compound, CLR 121225, for the treatment of solid tumors.

“Our lead alpha-emitting program, CLR 121225, has demonstrated excellent anti-tumor effects in preclinical studies, especially in pancreatic cancer,” Cellectar CEO James Caruso said in a statement. “Our agreement with ITM supports our strategic approach to ensure a continuous, high-quality supply of Actinium-225 required to advance our pipeline candidates and to fully explore the potential benefits of this targeted alpha therapy for cancer patients.”

ITM will supply Cellectar with the required quantities to facilitate the clinical development of its therapeutic medical-grade radioisotope, Ac-225.